Fisetin is a naturally occurring flavonoid found in fruits and vegetables (strawberries, apples, grapes) with senolytic properties, meaning it selectively eliminates senescent 'zombie' cells that accumulate with aging. It works through multiple mechanisms including mTORC1 pathway modulation, reduction of oxidative stress and inflammation, and SASP (senescence-associated secretory phenotype) factor inhibition. Primary research applications focus on anti-aging, neuroprotection, and metabolic health.

Overview

Fisetin (3,3',4',7-tetrahydroxyflavone) is a bioactive flavonol belonging to the polyphenol class of compounds, found naturally in various fruits and vegetables with the highest concentrations in strawberries, apples, persimmons, onions, and cucumbers. While it shares structural similarities with quercetin, fisetin has distinct pharmacological properties and has attracted intense scientific interest due to landmark research at the Mayo Clinic identifying it as the most potent natural senolytic agent tested.

The senolytic properties of fisetin represent its most exciting therapeutic potential. Senescent cells — aged, dysfunctional cells that resist apoptosis and secrete inflammatory factors (the senescence-associated secretory phenotype, or SASP) — accumulate with age and contribute to chronic disease and tissue deterioration. Studies in aged mice demonstrated that intermittent fisetin treatment reduced senescent cell burden, decreased age-related inflammation, improved tissue function, and extended median lifespan by approximately 10%. Clinical trials including the AFFIRM-LITE study are currently evaluating fisetin's senolytic effects in humans, particularly in older adults and individuals with age-related conditions.

Beyond senolytics, fisetin demonstrates robust neuroprotective activity, maintaining glutathione levels in neurons, inhibiting oxidative stress-induced cell death, and reducing neuroinflammation through modulation of NF-kB and MAPK pathways. Preclinical studies have shown benefits in models of Alzheimer's disease, stroke, and traumatic brain injury. Fisetin also supports metabolic health, inhibits cancer cell proliferation through multiple mechanisms, and has shown cardioprotective effects. Its relatively low bioavailability has led to development of enhanced formulations, and typical senolytic dosing protocols use intermittent high-dose regimens rather than continuous low-dose supplementation.

Mechanism of Action

Senolytic Activity

Fisetin (3,3',4',7-tetrahydroxyflavone) is a naturally occurring flavonoid found in strawberries, apples, and persimmons that has emerged as one of the most potent naturally-derived senolytic agents — compounds that selectively eliminate senescent cells. Fisetin inhibits the PI3K/Akt/mTOR and p53/p21/serpine anti-apoptotic pathways that senescent cells depend on for survival (the senescent cell anti-apoptotic pathways, or SCAPs). By suppressing Bcl-2, Bcl-xL, and other pro-survival proteins upregulated in senescent cells, fisetin reactivates apoptotic signaling, selectively clearing senescent cells while sparing proliferating cells (PMID: 30279143).

Kinase Inhibition & Anti-Inflammatory Pathways

Fisetin directly inhibits multiple kinases including CDK2/CDK4 (cyclin-dependent kinases), PI3K, Akt, and mTOR, disrupting pro-survival and pro-proliferative signaling in cancer and senescent cells. It potently suppresses NF-kB signaling by inhibiting IKK-beta and p65 nuclear translocation, reducing expression of TNF-alpha, IL-1beta, IL-6, COX-2, and iNOS. Fisetin also inhibits MAPK/ERK and JAK/STAT3 pathways, which drive inflammation and cell survival (PMID: 22178179).

Neuroprotective Mechanisms

Fisetin activates the Ras-ERK-CREB pathway in neurons, promoting neurotrophic factor expression (BDNF) and long-term potentiation. It maintains intracellular glutathione levels by upregulating the Nrf2/ARE pathway, protecting neurons against oxidative and excitotoxic damage. Fisetin also inhibits 5-lipoxygenase, reducing neuroinflammatory leukotriene production, and suppresses microglial activation (PMID: 24389933).

Epigenetic Modulation

Fisetin inhibits the activity of DNA methyltransferases (DNMTs) and histone deacetylases (HDACs), promoting re-expression of tumor suppressor genes silenced by epigenetic modification. It also modulates SIRT1 activity, enhancing deacetylation of p53 and NF-kB, contributing to both anti-cancer and anti-inflammatory effects (PMID: 24489112).

Reconstitution Calculator

Research

Safety Profile

Common Side Effects

• Generally well-tolerated at standard supplemental doses (100–500 mg/day)
• Mild gastrointestinal symptoms including nausea, bloating, and diarrhea reported infrequently
• Headache and mild dizziness occur occasionally
• Fisetin is a potent senolytic at high doses, and some users report transient fatigue or malaise during the initial days of intermittent high-dose protocols, sometimes described as a "senolytic flu"

Serious Adverse Effects

• Long-term human safety data is limited; most safety information derives from preclinical studies and short-term human trials
• At very high doses used in senolytic protocols (up to 20 mg/kg for multiple consecutive days), the safety profile is not fully characterized
• Theoretical concern for excessive clearance of senescent cells leading to impaired wound healing or tissue repair, though this has not been confirmed in humans
• Mild anticoagulant properties at high doses may increase bleeding risk in susceptible individuals
• Potential for kidney stress at extreme doses due to poor aqueous solubility and renal excretion of metabolites

Contraindications

• Individuals with bleeding disorders or on anticoagulant therapy should exercise caution due to mild blood-thinning properties
• Pregnant and breastfeeding women should avoid supplementation entirely due to lack of reproductive safety data and potential senolytic effects on developing tissues
• Patients with impaired kidney function should consult a physician, particularly before high-dose senolytic protocols
• Individuals scheduled for surgery should discontinue use at least one to two weeks prior

Drug Interactions

• Inhibits several cytochrome P450 enzymes (CYP1A2, CYP2C9, CYP3A4), potentially increasing serum concentrations of drugs metabolized through these pathways
• May potentiate the effects of anticoagulant and antiplatelet medications (warfarin, aspirin, clopidogrel)
• Potential interaction with chemotherapy agents; while some preclinical data suggests synergy, fisetin may also interfere with certain cytotoxic mechanisms
• May interact with immunosuppressants given its effects on inflammatory signaling pathways (NF-kB, PI3K/Akt)
• Possible additive effects with other senolytic compounds (dasatinib, quercetin) requiring careful dose management

Population-Specific Considerations

• Older adults are the primary population using fisetin for senolytic purposes; gradual dose escalation is advised
• Individuals with cancer should not self-administer fisetin without oncologist guidance due to complex interactions with tumor biology
• The Mayo Clinic AFFIRM trial and similar ongoing studies will provide more definitive safety data for high-dose intermittent use

Pharmacokinetic Profile